Crispr Therapeutics shares tumble after significant earnings miss
Michael Troutman, Chief Information Officer of Zurn Elkay Water Solutions Corp (NYSE:ZWS), sold 90,916 shares of common stock on July 31, 2025, for $3.9 million. The shares were sold at $43.01, near the stock’s 52-week high of $44.98. The $7.5 billion water solutions company has seen its shares surge 17% in the past week. According to InvestingPro analysis, the stock appears overvalued with a P/E ratio of 44.
On the same day, Troutman also exercised options to acquire a total of 90,916 shares of Zurn Elkay Water Solutions Corp common stock. These options were exercised at prices ranging from $9.69 to $33.05, totaling $1.18 million.
Following these transactions, Troutman directly owns 50,505 shares of ZWS and indirectly owns 1,890 shares through a 401(k) plan.
In other recent news, Zurn Water Solutions reported strong financial results for the second quarter of 2025, surpassing earnings expectations. The company achieved earnings per share of $0.42, exceeding the projected $0.36, which represents a 16.67% surprise. Revenue also surpassed estimates, coming in at $445 million compared to the anticipated $424.61 million. These results reflect a robust performance and have drawn positive attention from investors. In addition, Mizuho (NYSE:MFG) raised its price target for Zurn Water Solutions to $43 from $36, maintaining a Neutral rating. The research firm highlighted Zurn’s strong second-quarter performance, driven by tariff mitigation and organic sales growth of 8%. This growth is expected to continue into the third quarter despite some pre-buying due to tariff pricing increases. These developments underscore the company’s solid position and potential for sustained growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.